Micro-Dystrophin Protein Design for Dystrophin Function Restoration

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Duchenne muscular dystrophy (DMD) only slow the progression of the disease and do not effectively restore dystrophin function, leading to progressive muscle wasting and cardiac dysfunction, resulting in premature death.

Innovation Solution

Development of micro-dystrophin proteins comprising specific protein domains, such as an N-terminal domain, H1, SR1, SR16, SR17, SR23, SR24, H4, and CR domains, delivered via recombinant adeno-associated virus vectors, to restore dystrophin function and treat DMD, sarcopenia, and heart failure.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If micro-dystrophin proteins are delivered via recombinant adeno-associated virus vectors, then dystrophin function is restored and muscle contractility is enhanced, but the complexity of the treatment protocol increases

Engineering Contradiction:

Improvedystrophin function restorationVSAvoidtreatment protocol complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The micro-dystrophin protein is designed as a truncated version containing only the essential functional domains (actin-binding domain, spectrin-like repeats, and cysteine-rich domain), segmenting the full-length dystrophin to retain core functions while reducing complexity for viral vector packaging and delivery

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

Recombinant adeno-associated virus vectors serve as intermediary carriers to deliver the micro-dystrophin gene to muscle cells, mediating the transfer of genetic material and enabling restoration of dystrophin function without requiring direct protein administration

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If specific spectrin-like repeats (SR1, SR16, SR17, SR24) are included in micro-dystrophin, then neuronal nitric oxide synthase binding function is restored, but the protein size and manufacturing complexity increase

Engineering Contradiction:

ImprovenNOS binding functionVSAvoidprotein production complexity

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The micro-dystrophin construct incorporates specific spectrin-like repeats (SR1, SR16, SR17, SR24) that contain the neuronal nitric oxide synthase binding domain, providing localized functional quality in critical regions while omitting other non-essential portions of the full-length protein

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The protein sequence parameters are precisely defined to include only the necessary spectrin-like repeats with specific sequence identities (at least 80-90% identity to SEQ ID NO:4 or SEQ ID NO:5), optimizing the balance between functional completeness and manufacturability

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS12421285B2Micro-dystrophins and related methods of use

Publication Date: 2025.09.23 UNIV OF WASHINGTON

AI summary

Nucleotide sequences including a micro-dystrophin gene are provided. The micro-dystrophin genes may be operatively linked to a regulatory cassette. Methods of treating a subject having, or at risk of developing, muscular dystrophy, sarcopenia, heart disease, or cachexia are also provided. The methods may include administering a pharmaceutical composition including the micro-dystrophin gene and a delivery vehicle to a subject. Further, the methods may include administering the pharmaceutical composition a subject having Duchenne muscular dystrophy or Becker muscular dystrophy.